1 August 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Directorate changes
Proteome Sciences (AIM:PRM), is pleased to announce the appointment of Dr Ursula Ney as a Non-executive Director of the Company, with immediate effect, replacing Professor William Dawson who is standing down after providing 20 years of valuable service to the Company.
Dr Ney has over 30 years' experience in the pharmaceuticals industry, this includes 20 years in leadership roles in the biotech sector. She has worked with many of the major US pharma companies and has a range of skills including product development, business development, partnering and M&A. Dr Ney has worked for both public and private companies including Celltech, Roche, Sandoz and as Chief Operating Officer of Antisoma plc. She is currently a Non-executive Director of Discuva, a drug discovery company focused on the creation of next generation targeted antimicrobials against new emerging and drug-resistant bacterial pathogens.
Commenting on the appointment, Chief Executive Officer, Jeremy Haigh, said "We are delighted to welcome Dr Ney to the Board of Proteome Sciences. Her extensive experience of the bioscience environment, gathered over many years in a range of senior positions within large and small companies, makes her ideally suited to a role on the Board at this pivotal stage in the Company's evolution. I look forward to working closely with her over the coming months. I would also like to take this opportunity to thank Professor Dawson for his outstanding service as a Director of the Company since 1997; Bill's scientific insight has been a cornerstone of our endeavour for many years and we hope to realise his vision in the months and years to come."
Dr Ney said "I am delighted to be joining the Board of Proteome Sciences at this exciting and challenging time for the company and I look forward to working with all the Board and team to realise the potential of the proteomics platform."
As announced with the interim results on 25 July, and following the resignation of Geoff Ellis as Finance Director and Company Secretary, we are pleased to confirm that Stefan Fuhrmann has been appointed Interim Finance Director. Mr Fuhrmann has strong financial and management reporting skills and qualified as an accountant in the UK. Victoria Birse has been appointed Company Secretary, having joined Proteome Sciences in March 2015.
For further information:
Proteome Sciences plc |
Jeremy Haigh, Chief Executive Officer |
|
Ian Pike, Chief Scientific Officer |
Tel: +44 (0)20 7043 2116 |
|
|
|
|
finnCap Limited (Nominated Adviser & Broker) |
Geoff Nash/James Thompson Tony Quirke (Broking) |
Tel: +44 (0)20 7220 0500 |
|
IFC Advisory (Financial PR and IR) |
|
|
Tim Metcalfe/Graham Herring/Miles Nolan |
Tel: +44 (0)20 3053 8671 |
|
|
|
|
|
|
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
Additional information on Dr Ursula Mary Ney
The following additional information is provided in accordance with Schedule 2(g) of the AIM Rules for Companies:
Current and past Directorships for Dr Ursula Mary Ney, aged 65:
Current |
Previous (last five years) |
Discuva Ltd |
Genkyotex SA |
|
|
|
|
|
|
There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.
